RetroSense Therapeutics

Last updated: April 19, 2024

Sean Ainsworth, CEO
Sean Ainsworth, CEO
Country: USA | Funding: $17M (+)

Website: http://retrosense.com

RetroSense Therapeutics is a biotechnology company that is developing a game-changing gene therapy to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). There are currently no FDA approved therapies to improve or restore vision in patients with these retinal degenerative conditions.